TITLE

Managing Product Supply Risks

AUTHOR(S)
Abraham, Sushil
PUB. DATE
April 2012
SOURCE
Pharmaceutical Technology;Apr2012, Vol. 36 Issue 4, p102
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the use of geographic diversification and legacy technology transfers to deflect drug shortage in the U.S. It mentions that the U.S. Food and Drug Administration, together with the pharmaceutical industry, were asked by U.S. President Barack Obama to provide a solution on drug scarcity. The establishment of additional drug manufacturing plants is one strategic approach taken in geographic diversification, as well as the sustainment of drug quality and safety.
ACCESSION #
74443838

 

Related Articles

  • Executive Order 13588--Reducing Prescription Drug Shortages. OBAMA, BARACK // Daily Compilation of Presidential Documents;10/31/2011, p1 

    The article presents an executive order of U.S. President Barack Obama that addresses drug scarcities. Obama suggested that pharmaceuticals must inform the U.S. Food and Drug Administration (FDA) and the American public on medicine shortages early to aid medical facilities, doctors, and patients...

  • Packaging Serialization Update. Barlas, Stephen // Contract Pharma;Mar2012, Vol. 14 Issue 2, p60 

    The article discusses the move of the U.S. Food and Drug Administration (FDA) to revise its 2004 pharmaceutical package barcode rule that will mandate the pharmaceutical industry to put a linear barcode with the National Drug Code. It notes that such move stems in part of the Executive Order...

  • Pharma, FDA and the Dems. Lerner, Ivan // ICIS Chemical Business;1/26/2009, Vol. 275 Issue 4, p30 

    The article offers on the possible impact of the new U.S. President Barack Obama administration on the pharmaceutical industry. It is expected that changes are coming in the relationship between the U.S. federal government and the major pharmaceutical manufacturers, as the administration of...

  • UNITED STATES PHARMACEUTICALS & HEATHCARE REPORT.  // U.S. Pharma & Healthcare Report;2013 1st Quarter, Issue 1, p1 

    The article reviews the performance of the U.S. pharmaceuticals and healthcare sectors as of the first quarter of 2013 and also provides 10-year forecasts to 2021. Some of the key trends and developments are the approval of 35 new drugs by the Food and Drug Administration (FDA) during the...

  • Obama Acts On Shortages Of Medicines.  // Chain Drug Review;11/21/2011, Vol. 33 Issue 20, p59 

    The article reports that president Barack Obama has signed an order that directs the U.S. Food and Drug Administration to take action in preventing prescription drug shortages.

  • POTENTIAL SAVINGS.  // Business Insurance;5/25/2015, Vol. 49 Issue 11, p0027 

    The article presents figures showing savings that could be realized from the introduction of biosimilar drugs in the U.S. including a reduction in direct spending on biologics from 2014 to 2041, the number of products developed in the U.S. Food and Drug Administration's (FDA) biosimilar...

  • FDA and Justice Department. Address Drug Quality Concerns. Wechsler, Jill // Pharmaceutical Technology;Feb2012, Vol. 36 Issue 2, p24 

    The article discusses the move of the Food and Drug Administration (FDA) and the Department of Justice to improve their enforcement strategies to address drug quality concerns in the U.S. It notes the significance of President Barack Obama's broader campaign against healthcare fraud and...

  • Age-Related Disorder. Lowe, Derek B. // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p30 

    The article focuses on disorders associated to aging and the discovery of drugs for these diseases by pharmaceutical companies in the U.S. It notes the scrutiny whether a drugmaker intends to sell medication for unapproved uses. It considers the ability of the Food and Drug Administration (FDA)...

  • Will medications be safer in the future? Erickson, Amy K. // Pharmacy Today;Nov2010, Vol. 16 Issue 11, p40 

    The article focuses on issues faced by the U.S. Food and Drug Administration (FDA) concerning safety and quality of drugs manufactured abroad. It highlights on the regulatory system implemented by FDA to ensure that products made outside the U.S. meet the standards of the pharmaceutical...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics